Get Tecentriq (Atezolizumab) Covered by Blue Cross Blue Shield in Virginia: Complete Prior Authorization Guide
Answer Box: Tecentriq (atezolizumab) requires prior authorization from Blue Cross Blue Shield in Virginia for all 2024 plans. Success depends on meeting FDA-approved indication criteria, proper PD-L1 testing (≥1% for adjuvant NSCLC, ≥50% for first-line metastatic), and comprehensive documentation. If denied, you have 120 days to file an external review